【ChiCTR2300072972】Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
ChiCTR2300072972
结束
/
/
/
2023-06-29
/
/
Covid 19
Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
This study aims to determine the association between laboratory parameters of COVID-19 patients and clinical disease severity to provide applicable information to improved treatment strategies.
队列研究
回顾性研究
N/A
N/A
Self-funded
/
296
/
2020-01-01
2022-01-23
/
1. The study population comprised patients with confirmed or suspected SARS-CoV-2 infection according to the Colombian consensus of attention, diagnostic, and treatment of COVID-19 infection, an expert consensus; 2. Patients were tested for SARS-CoV-2, and the diagnosis was made using the real-time reverse transcriptase-polymerase chain reaction (rt-PCR) test or antigens for SARS-CoV-2 test; 3. All hospitalized patients with more than 5 days and with a positive RT-PCR assay or antigens test for SARS-CoV-2 were included in the study; 4. Positive COVID-19 diagnosis patients lists were recollected on a database used by the Hospital Universitario Fundación Santa Fe de Bogotá; 5. Decisions about the necessity of hospitalization were made by emergency physicians in accordance with the same guidelines, and the use of severity-based classification variables, patient clinical state, and paraclinical information, independent of inpatient bed availability; 6. Patients were only included if requiring hospitalization was available at the emergency department, or hospitalization bed, or intensive care unit bed became available.;
请登录查看1. Transferred patients were not included; 2. Those patients who did not undergo molecular tests or tested negative were excluded from the study; 3.Patients who have the infection for the second time.;
请登录查看MD pathologist; Fundación Santa Fé de Bogotá
/
MD pathologist; Fundación Santa Fé de Bogotá的其他临床试验
MD pathologist; Fundación Santa Fé de Bogotá的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
同适应症药物临床试验
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

